MOUNTAIN VIEW, Calif., July 25, 2018 – Namocell Inc., a leading provider of high-performance single cell dispensing and sorting platforms for life science applications, today announced it has entered into a distribution agreement with BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), to distribute Namocell’s Namo Single Cell Dispenser in the Netherlands, Belgium and Luxembourg (collectively, the “BeNeLux”) market.
“The Netherlands, Belgium and Luxembourg are fast-growing markets in single cell genomics and a number of other single cell related bioscience research fields, with world-renowned bioscience institutions. Namocell is dedicated to providing the fastest way to a single cell. We are excited to bring our Namo Single Cell Dispenser to the BeNeLux market. Our Namo can dispense single cells into a 96-well plate in less than a minute and a 384-well plate in less than 3 minutes. Its low sorting pressure preserves cell viability. Among other advantages over traditional cell sorters, our proprietary cell cartridge makes sterile sorting easy and prevents system clogging.” said Namocell CEO Dr. Junyu Lin. “BIOKÉ is a leading player in the BeNeLux market with a long history of delivering outstanding customer services. We look forward to working with BIOKÉ in serving bioscience researchers in the BeNeLux.”
“We are very excited to bring Namocell’s industry-leading single cell dispensing and sorting instruments to customers in the BeNelux,” said Koos Kranenborg, Director of Marketing & Sales – BIOKÉ. “The market is in high need of an easy-to-operate and high-performance single cell dispensing and sorting instrument. The Namo Single Cell Dispenser is extremely user-friendly, gentle to the cells, and can handle very low sample volume that traditional cell sorters cannot handle. We are eager to bring Namo to researchers to make single cell dispensing and sorting easy for them!”
Namocell Inc. provides the fastest way to a single cell. We are a leading provider of single cell dispensing and sorting technology based in the Silicon Valley, the United States. Our proprietary microfluidic-based single cell platforms simplify and empower a wide range of life science research and clinical applications, such as cancer immunotherapy, cell line development, rare cell isolation, CRISPR, single cell genomics, and monoclonal antibody isolation.
Founded in 2004, BIOKÉ is a leading provider of innovative and high-quality products in the life science industry throughout Europe. BIOKÉ delivers unique and high-performance applications and workflows for genomics, protein analysis and cell biology. In July 2009 Cell Signaling Technology, Inc. (CST) – the market leader in the development of high quality antibody products and technologies – acquired BIOKÉ BV and BIOKÉ became a business unit of Cell Signaling Technology Europe (CST EU), with hold offices in Leiden, the Netherlands. For additional information please visit the BIOKÉ website at www.bioke.com.